免疫治疗药物市场 - 按药物类型、应用、给药途径、配销通路- 全球预测

Immunotherapy Drugs Market - By Drug Type, Application, Route of Administration, Distribution Channel - Global Forecast

出版日期: 2024年05月31日 | 出版商:

Global Market Insights Inc. | 英文 120 Pages | 商品交期: 2-3个工作天内

价格

简介目录

受领先製药公司不断增加的拨款和许可的影响，全球免疫疗法药物市场 2024 年至 2032 年间的复合年增长率将达到 10.4%。这些金融投资和监管批准正在加速创新免疫疗法的开发和可用性。政府机构和私人组织的资助正在促进先进研究，使公司能够探索新的治疗目标并完善治疗方案。同时，监管机构越来越快地批准有前景的免疫疗法药物，并认识到它们彻底改变癌症治疗和其他自体免疫疾病的潜力。

例如，2022 年 7 月，美国食品药物管理局 (FDA) 延长了罗斯威尔公园综合癌症中心开发的脑癌免疫疗法 SurVaxM 的孤儿药资格。

这些支持措施正在增加临床试验机会并加速新疗法的市场进入。随着领先公司获得更多资助并成功应对监管环境，免疫疗法药物的管道不断扩大，满足了对有效、有针对性的治疗日益增长的需求。财政支持和监管便利之间的协同作用正在推动市场成长，将免疫疗法定位为未来医疗的关键组成部分。

整个免疫治疗药物产业根据药物类型、应用、给药途径、配销通路和地区进行分类。

根据药物类型，疫苗领域的免疫疗法药物市场收入从2024 年到2032 年将实现令人称讚的复合年增长率。。随着正在进行的研究和临床试验证明其具有提高治疗效果和患者预后的潜力，癌症疫苗正在获得越来越多的关注。人们日益关注免疫疗法作为可行的治疗选择，再加上预防措施和个人化方法的推动，正在推动市场成长。随着製药公司投资开发和商业化这些创新疫苗，对免疫疗法药物的需求将大幅上升。

在应用方面，自体免疫疾病领域将在2024年至2032年出现显着成长。新的希望。随着研究更多地揭示免疫系统在这些疾病中的作用，免疫疗法在控制症状和改变疾病进展方面变得越来越有效。自体免疫疾病的日益普及以及对有针对性的个人化治疗的需求推动了市场的成长。研究和开发的投资进一步加速了新型免疫疗法的上市，改善患者的治疗效果，并推动市场扩张。

2024年至2032年，欧洲免疫疗法药物市场将呈现显着的复合年增长率。欧盟的支持性监管环境和创新疗法的资助计画进一步增强了这一需求。此外，患者和医疗保健提供者对免疫疗法益处的认识不断提高，推动了市场扩张。随着欧洲製药公司投资研发并合作进行临床试验，对尖端免疫疗法药物的需求可能会继续呈上升趋势。

主要趋势
北美洲
- 我们
- 加拿大
欧洲
- 德国
- 英国
- 法国
- 西班牙
- 义大利
- 荷兰
- 欧洲其他地区
亚太地区
- 中国
- 日本
- 印度
- 澳洲
- 韩国
- 亚太地区其他地区
拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 拉丁美洲其他地区
中东和非洲
- 南非
- 沙乌地阿拉伯
- 阿联酋
- 中东和非洲其他地区

第 10 章：公司简介

AbbVie Inc.
Amgen Inc.
AstraZeneca
Bayer AG
Boehringer Ingelheim
Eli Lilly and Company
F. Hoffmann-La Roche Ltd.
Genmab A/S
GSK plc
Immatics N.V.
Johnson & Johnson Services, Inc.
Merck & Co., Inc.
Novartis AG
Pfizer, Inc.
Sanofi

简介目录

Product Code: 9713

Global Immunotherapy Drugs Market will witness 10.4% CAGR between 2024 and 2032, influenced by rising grants and permissions from leading pharmaceutical companies. These financial investments and regulatory approvals are accelerating the development and availability of innovative immunotherapy treatments. Grants from government bodies and private organizations are facilitating advanced research, enabling companies to explore new therapeutic targets and refine treatment protocols. Concurrently, regulatory agencies are increasingly fast-tracking approvals for promising immunotherapy drugs, recognizing their potential to revolutionize cancer treatment and other autoimmune disorders.

For instance, in July 2022, the U.S. Food and Drug Administration (FDA) extended the orphan drug designation for SurVaxM, an immunotherapy for brain cancer developed at Roswell Park Comprehensive Cancer Center.

These supportive measures are enhancing clinical trial opportunities and expediting market entry for novel therapies. As leading companies secure more grants and navigate regulatory landscapes successfully, the pipeline for immunotherapy drugs expands, meeting the growing demand for effective, targeted treatments. This synergy between financial support and regulatory facilitation is driving market growth, positioning immunotherapy as a pivotal component in the future of medical treatments.

The overall Immunotherapy Drugs Industry is classified based on the drug type, application, route of administration, distribution channel, and region.

Based on drug type, the immunotherapy drugs market revenue from the vaccines segment will register a commendable CAGR from 2024 to 2032. These vaccines, designed to stimulate the immune system to target and destroy cancer cells, represent a significant leap forward in personalized medicine. With ongoing research and clinical trials demonstrating their potential to enhance treatment efficacy and patient outcomes, cancer vaccines are gaining traction. The growing focus on immunotherapy as a viable treatment option, combined with the push for preventive measures and personalized approaches, is fueling market growth. As pharmaceutical companies invest in developing and commercializing these innovative vaccines, the demand for immunotherapy drugs will rise substantially.

In terms of application, the auto immune diseases segment will witness appreciable growth from 2024 to 2032. These drugs, which harness the body's immune system to target and modify disease mechanisms, offer new hope for conditions like rheumatoid arthritis, multiple sclerosis, and lupus. As research uncovers more about the immune system's role in these disorders, immunotherapies are becoming increasingly effective in managing symptoms and altering disease progression. The growing prevalence of autoimmune diseases and the need for targeted, personalized treatments drive market growth. Investments in research and development are further accelerating the availability of novel immunotherapies, enhancing patient outcomes, and fueling market expansion.

Europe immunotherapy drugs market will exhibit a notable CAGR from 2024 to 2032. European countries are increasingly adopting immunotherapies due to their promising results in targeting specific cancer cells and improving patient outcomes. The European Union's supportive regulatory environment and funding initiatives for innovative therapies further bolster this demand. In addition, rising awareness among patients and healthcare providers about the benefits of immunotherapy fuels market expansion. As European pharmaceutical companies invest in research and development and collaborate on clinical trials, the demand for cutting-edge immunotherapy drugs could continue its upward trajectory.

Chapter 1 Methodology & Scope

1.1 Market scope & definitions
1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
1.3 Base estimates & calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources

Chapter 2 Executive Summary

2.1 Industry 360° synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Increasing prevalence of chronic diseases
  - 3.2.1.2 Growing adoption of combination therapies
  - 3.2.1.3 Technological advancements
- 3.2.2 Industry pitfalls & challenges
  - 3.2.2.1 High cost of treatment
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Pipeline analysis
3.6 Porter's analysis
3.7 PESTEL analysis
3.8 Future market trends

Chapter 4 Competitive Landscape, 2023

4.1 Introduction
4.2 Company market share analysis
4.3 Company matrix analysis
4.4 Competitive analysis of major market players
4.5 Competitive positioning matrix
4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Drug Type, 2021 - 2032 ($ Mn)

5.1 Key trends
5.2 Monoclonal antibodies
5.3 Vaccines
5.4 Check point inhibitor
5.5 Interferons alpha & beta
5.6 Interleukins
5.7 Other drug types

Chapter 6 Market Estimates and Forecast, By Application, 2021 - 2032 ($ Mn)

6.1 Key trends
6.2 Cancer
6.3 Autoimmune diseases
6.4 Infectious diseases
6.5 Other applications

Chapter 7 Market Estimates and Forecast, By Route of Administration, 2021 - 2032 ($ Mn)

7.1 Key trends
7.2 Intravenous
7.3 Subcutaneous
7.4 Oral

Chapter 8 Market Estimates and Forecast, By Distribution Channel, 2021 - 2032 ($ Mn)

8.1 Key trends
8.2 Hospital pharmacy
8.3 Brick and mortar
8.4 E-commerce

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

9.1 Key trends
9.2 North America
- 9.2.1 U.S.
- 9.2.2 Canada
9.3 Europe
- 9.3.1 Germany
- 9.3.2 UK
- 9.3.3 France
- 9.3.4 Spain
- 9.3.5 Italy
- 9.3.6 Netherlands
- 9.3.7 Rest of Europe
9.4 Asia Pacific
- 9.4.1 China
- 9.4.2 Japan
- 9.4.3 India
- 9.4.4 Australia
- 9.4.5 South Korea
- 9.4.6 Rest of Asia Pacific
9.5 Latin America
- 9.5.1 Brazil
- 9.5.2 Mexico
- 9.5.3 Argentina
- 9.5.4 Rest of Latin America
9.6 Middle East and Africa
- 9.6.1 South Africa
- 9.6.2 Saudi Arabia
- 9.6.3 UAE
- 9.6.4 Rest of Middle East and Africa